Icon (NASDAQ:ICLR) Releases FY 2026 Earnings Guidance

Icon (NASDAQ:ICLR) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 10.000-11.000 for the period, compared to the consensus earnings per share estimate of 10.380. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $8.0 billion.

Icon Price Performance

ICLR stock opened at $170.00 on Friday. The stock has a market capitalization of $13.02 billion, a P/E ratio of 30.25, a PEG ratio of 8.34 and a beta of 1.22. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.14 and a current ratio of 1.14. Icon has a one year low of $66.57 and a one year high of $211.00. The company has a 50 day moving average price of $146.22 and a two-hundred day moving average price of $137.01.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ICLR shares. TD Cowen lifted their price objective on Icon from $164.00 to $197.00 and gave the company a “buy” rating in a research note on Thursday, June 25th. Leerink Partners set a $145.00 price objective on shares of Icon in a research report on Thursday, May 28th. Barclays increased their price target on Icon from $160.00 to $175.00 and gave the company an “equal weight” rating in a report on Thursday, June 25th. Weiss Ratings downgraded Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Finally, Robert W. Baird lifted their price target on shares of Icon from $168.00 to $186.00 and gave the stock an “outperform” rating in a research note on Thursday, June 25th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Icon presently has a consensus rating of “Hold” and an average target price of $173.19.

Institutional Investors Weigh In On Icon

A number of large investors have recently bought and sold shares of ICLR. EFG International AG acquired a new stake in shares of Icon in the fourth quarter worth about $27,000. Johnson Financial Group Inc. acquired a new position in Icon during the third quarter valued at approximately $71,000. Quadrant Capital Group LLC bought a new position in Icon in the 3rd quarter worth $78,000. Geneos Wealth Management Inc. boosted its holdings in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after acquiring an additional 56 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its holdings in shares of Icon by 198.8% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 487 shares of the medical research company’s stock worth $89,000 after buying an additional 324 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.